APO Research
Talk to an analyst

APO RESEARCH · REPORT

Uterine Fibroid Embolization Agents

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Uterine Fibroid Embolization Agents Industry Growth and Trends Forecast to 2032

19 December 202596 pages

Choose your research edition.

Industry ResearchUterine Fibroid Embolization Agents Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Uterine Fibroid Embolization Agents Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Uterine Fibroid Embolization Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Uterine Fibroid Embolization Agents Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Uterine Fibroid Embolization Agents Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Uterine Fibroid Embolization Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Uterine Fibroid Embolization Agents include Pfizer, Boston Scientific Corporation, Nippon Kayaku, Merit Medical Systems, Cook Medical and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Uterine Fibroid Embolization Agents market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Uterine Fibroid Embolization Agents market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Uterine Fibroid Embolization Agents market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Uterine Fibroid Embolization Agents.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Uterine Fibroid Embolization Agents market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Uterine Fibroid Embolization Agents Market by Company

Pfizer

Boston Scientific Corporation

Nippon Kayaku

Merit Medical Systems

Cook Medical

Astellas Pharma

Uterine Fibroid Embolization Agents Segment by Type

Polymethyl Methacrylate (PMMA) Microspheres

Polyvinyl Alcohol (PVA) Particles

Gelatin Sponge

Trisacryl Gelatin Microspheres (TAGM)

Others

Uterine Fibroid Embolization Agents Segment by Application

Hospital

Surgical Centers

Clinical Research Institutes

Others

Uterine Fibroid Embolization Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uterine Fibroid Embolization Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Uterine Fibroid Embolization Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uterine Fibroid Embolization Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Uterine Fibroid Embolization Agents manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Uterine Fibroid Embolization Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Polymethyl Methacrylate (PMMA) Microspheres Table 2. Major Company of Polyvinyl Alcohol (PVA) Particles Table 3. Major Company of Gelatin Sponge Table 4. Major Company of Trisacryl Gelatin Microspheres (TAGM) Table 5. Major Company of Others Table 6. Global Uterine Fibroid Embolization Agents Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 8. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type (2021-2026) Table 9. Global Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 10. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Type (2021-2026) Table 11. Global Uterine Fibroid Embolization Agents Price by Type (2021-2026) & (US$/Unit) Table 12. Global Uterine Fibroid Embolization Agents Sales by Type (2027-2032) & (K Units) Table 13. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type (2027-2032) Table 14. Global Uterine Fibroid Embolization Agents Sales by Type (2027-2032) & (US$ Million) Table 15. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Type (2027-2032) Table 16. Global Uterine Fibroid Embolization Agents Price by Type (2027-2032) & (US$/Unit) Table 17. North America Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 18. North America Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 20. Europe Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 24. Latin America Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (US$ Million) Table 27. Uterine Fibroid Embolization Agents Industry Trends Table 28. Uterine Fibroid Embolization Agents Industry Drivers Table 29. Uterine Fibroid Embolization Agents Industry Opportunities and Challenges Table 30. Uterine Fibroid Embolization Agents Industry Restraints Table 31. Global Uterine Fibroid Embolization Agents Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Uterine Fibroid Embolization Agents Revenue Market Share by Company (2021-2026) Table 33. Global Uterine Fibroid Embolization Agents Sales by Company (2021-2026) & (K Units) Table 34. Global Uterine Fibroid Embolization Agents Sales Share by Company (2021-2026) Table 35. Global Uterine Fibroid Embolization Agents Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Uterine Fibroid Embolization Agents Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Uterine Fibroid Embolization Agents Major Company Production Sites and Headquarters Table 38. Global Uterine Fibroid Embolization Agents Company, Product Type & Application Table 39. Global Uterine Fibroid Embolization Agents Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Uterine Fibroid Embolization Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Uterine Fibroid Embolization Agents Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Uterine Fibroid Embolization Agents Sales by Region (2021-2026) & (K Units) Table 44. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Region (2021-2026) Table 45. Global Uterine Fibroid Embolization Agents Sales by Region (2021-2026) & (US$ Million) Table 46. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Region (2021-2026) Table 47. Global Uterine Fibroid Embolization Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Uterine Fibroid Embolization Agents Sales by Region (2027-2032) & (K Units) Table 49. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Region (2027-2032) Table 50. Global Uterine Fibroid Embolization Agents Sales by Region (2027-2032) & (US$ Million) Table 51. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Region (2027-2032) Table 52. Global Uterine Fibroid Embolization Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Uterine Fibroid Embolization Agents Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 55. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application (2021-2026) Table 56. Global Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 57. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Application (2021-2026) Table 58. Global Uterine Fibroid Embolization Agents Price by Application (2021-2026) & (US$/Unit) Table 59. Global Uterine Fibroid Embolization Agents Sales by Application (2027-2032) & (K Units) Table 60. Global Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application (2027-2032) Table 61. Global Uterine Fibroid Embolization Agents Sales by Application (2027-2032) & (US$ Million) Table 62. Global Uterine Fibroid Embolization Agents Sales Market Share in Value by Application (2027-2032) Table 63. Global Uterine Fibroid Embolization Agents Price by Application (2027-2032) & (US$/Unit) Table 64. North America Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 65. North America Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 67. Europe Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 71. Latin America Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (US$ Million) Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Pfizer Uterine Fibroid Embolization Agents Product Portfolio Table 78. Pfizer Recent Development Table 79. Boston Scientific Corporation Company Information Table 80. Boston Scientific Corporation Business Overview Table 81. Boston Scientific Corporation Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Boston Scientific Corporation Uterine Fibroid Embolization Agents Product Portfolio Table 83. Boston Scientific Corporation Recent Development Table 84. Nippon Kayaku Company Information Table 85. Nippon Kayaku Business Overview Table 86. Nippon Kayaku Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Nippon Kayaku Uterine Fibroid Embolization Agents Product Portfolio Table 88. Nippon Kayaku Recent Development Table 89. Merit Medical Systems Company Information Table 90. Merit Medical Systems Business Overview Table 91. Merit Medical Systems Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merit Medical Systems Uterine Fibroid Embolization Agents Product Portfolio Table 93. Merit Medical Systems Recent Development Table 94. Cook Medical Company Information Table 95. Cook Medical Business Overview Table 96. Cook Medical Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cook Medical Uterine Fibroid Embolization Agents Product Portfolio Table 98. Cook Medical Recent Development Table 99. Astellas Pharma Company Information Table 100. Astellas Pharma Business Overview Table 101. Astellas Pharma Uterine Fibroid Embolization Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Astellas Pharma Uterine Fibroid Embolization Agents Product Portfolio Table 103. Astellas Pharma Recent Development Table 104. North America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 105. North America Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 106. North America Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2026) Table 107. North America Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032) & (K Units) Table 108. North America Uterine Fibroid Embolization Agents Sales Market Share Forecast by Country (2027-2032) Table 109. North America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 110. North America Uterine Fibroid Embolization Agents Market Size by Country (2021-2026) & (US$ Million) Table 111. North America Uterine Fibroid Embolization Agents Market Share by Country (2021-2026) Table 112. North America Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 113. North America Uterine Fibroid Embolization Agents Market Share Forecast by Country (2027-2032) Table 114. Europe Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 115. Europe Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 116. Europe Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2026) Table 117. Europe Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032) & (K Units) Table 118. Europe Uterine Fibroid Embolization Agents Sales Market Share Forecast by Country (2027-2032) Table 119. Europe Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. Europe Uterine Fibroid Embolization Agents Market Size by Country (2021-2026) & (US$ Million) Table 121. Europe Uterine Fibroid Embolization Agents Market Share by Country (2021-2026) Table 122. Europe Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. Europe Uterine Fibroid Embolization Agents Market Share Forecast by Country (2027-2032) Table 124. Asia-Pacific Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 125. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 126. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2026) Table 127. Asia-Pacific Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032) & (K Units) Table 128. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Uterine Fibroid Embolization Agents Market Size by Country (2021-2026) & (US$ Million) Table 131. Asia-Pacific Uterine Fibroid Embolization Agents Market Share by Country (2021-2026) Table 132. Asia-Pacific Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Asia-Pacific Uterine Fibroid Embolization Agents Market Share Forecast by Country (2027-2032) Table 134. Latin America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 135. Latin America Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 136. Latin America Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2026) Table 137. Latin America Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032) & (K Units) Table 138. Latin America Uterine Fibroid Embolization Agents Sales Market Share Forecast by Country (2027-2032) Table 139. Latin America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Latin America Uterine Fibroid Embolization Agents Market Size by Country (2021-2026) & (US$ Million) Table 141. Latin America Uterine Fibroid Embolization Agents Market Share by Country (2021-2026) Table 142. Latin America Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Latin America Uterine Fibroid Embolization Agents Market Share Forecast by Country (2027-2032) Table 144. Middle East and Africa Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 145. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 146. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2026) Table 147. Middle East and Africa Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032) & (K Units) Table 148. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Uterine Fibroid Embolization Agents Market Size by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Uterine Fibroid Embolization Agents Market Share by Country (2021-2026) Table 152. Middle East and Africa Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Middle East and Africa Uterine Fibroid Embolization Agents Market Share Forecast by Country (2027-2032) Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Uterine Fibroid Embolization Agents Distributors List Table 157. Uterine Fibroid Embolization Agents Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Uterine Fibroid Embolization Agents Image Figure 2. Global Uterine Fibroid Embolization Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Uterine Fibroid Embolization Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Uterine Fibroid Embolization Agents Sales (2021-2032) & (K Units) Figure 5. Polymethyl Methacrylate (PMMA) Microspheres Image Figure 6. Global Polymethyl Methacrylate (PMMA) Microspheres Sales YoY Growth (2021-2032) & (K Units) Figure 7. Polyvinyl Alcohol (PVA) Particles Image Figure 8. Global Polyvinyl Alcohol (PVA) Particles Sales YoY Growth (2021-2032) & (K Units) Figure 9. Gelatin Sponge Image Figure 10. Global Gelatin Sponge Sales YoY Growth (2021-2032) & (K Units) Figure 11. Trisacryl Gelatin Microspheres (TAGM) Image Figure 12. Global Trisacryl Gelatin Microspheres (TAGM) Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Uterine Fibroid Embolization Agents Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Uterine Fibroid Embolization Agents Market Share by Type 2025 VS 2032 Figure 17. North America Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type in 2025 Figure 18. North America Uterine Fibroid Embolization Agents Sales Market Share in Value by Type in 2025 Figure 19. Europe Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type in 2025 Figure 20. Europe Uterine Fibroid Embolization Agents Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share in Value by Type in 2025 Figure 23. Latin America Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Uterine Fibroid Embolization Agents Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Uterine Fibroid Embolization Agents Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Surgical Centers Image Figure 32. Global Surgical Centers Sales YoY Growth (2021-2032) & (K Units) Figure 33. Clinical Research Institutes Image Figure 34. Global Clinical Research Institutes Sales YoY Growth (2021-2032) & (K Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Uterine Fibroid Embolization Agents Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Uterine Fibroid Embolization Agents Market Share by Application 2025 VS 2032 Figure 39. North America Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application in 2025 Figure 40. North America Uterine Fibroid Embolization Agents Sales Market Share in Value by Application in 2025 Figure 41. Europe Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application in 2025 Figure 42. Europe Uterine Fibroid Embolization Agents Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Uterine Fibroid Embolization Agents Sales Market Share in Value by Application in 2025 Figure 45. Latin America Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Uterine Fibroid Embolization Agents Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share in Value by Application in 2025 Figure 49. North America Uterine Fibroid Embolization Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Uterine Fibroid Embolization Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Uterine Fibroid Embolization Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Uterine Fibroid Embolization Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Uterine Fibroid Embolization Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Uterine Fibroid Embolization Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Uterine Fibroid Embolization Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Uterine Fibroid Embolization Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Uterine Fibroid Embolization Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Uterine Fibroid Embolization Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Uterine Fibroid Embolization Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Uterine Fibroid Embolization Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Uterine Fibroid Embolization Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Uterine Fibroid Embolization Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Uterine Fibroid Embolization Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Uterine Fibroid Embolization Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Uterine Fibroid Embolization Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Uterine Fibroid Embolization Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Uterine Fibroid Embolization Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Uterine Fibroid Embolization Agents Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Uterine Fibroid Embolization Agents Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Polymethyl Methacrylate (PMMA) Microspheres
  • Polyvinyl Alcohol (PVA) Particles
  • Gelatin Sponge
  • Trisacryl Gelatin Microspheres (TAGM)
  • Others
Applications
  • Hospital
  • Surgical Centers
  • Clinical Research Institutes
  • Others
Companies covered
  • Pfizer
  • Boston Scientific Corporation
  • Nippon Kayaku
  • Merit Medical Systems
  • Cook Medical
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Uterine Fibroid Embolization Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Uterine Fibroid Embolization Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Uterine Fibroid Embolization Agents Market by Type
  6. 1.3.1 Polymethyl Methacrylate (PMMA) Microspheres
  7. 1.3.2 Polyvinyl Alcohol (PVA) Particles
  8. 1.3.3 Gelatin Sponge
  9. 1.3.4 Trisacryl Gelatin Microspheres (TAGM)
  10. 1.3.5 Others
  11. 1.4 Global Uterine Fibroid Embolization Agents Market Size by Type
  12. 1.4.1 Global Uterine Fibroid Embolization Agents Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Uterine Fibroid Embolization Agents Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Uterine Fibroid Embolization Agents Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Uterine Fibroid Embolization Agents Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Uterine Fibroid Embolization Agents Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Uterine Fibroid Embolization Agents Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Uterine Fibroid Embolization Agents Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Uterine Fibroid Embolization Agents Industry Trends
  2. 2.2 Uterine Fibroid Embolization Agents Industry Drivers
  3. 2.3 Uterine Fibroid Embolization Agents Industry Opportunities and Challenges
  4. 2.4 Uterine Fibroid Embolization Agents Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Uterine Fibroid Embolization Agents Revenue (2021-2026)
  2. 3.2 Global Top Players by Uterine Fibroid Embolization Agents Sales (2021-2026)
  3. 3.3 Global Top Players by Uterine Fibroid Embolization Agents Price (2021-2026)
  4. 3.4 Global Uterine Fibroid Embolization Agents Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Uterine Fibroid Embolization Agents Major Company Production Sites & Headquarters
  6. 3.6 Global Uterine Fibroid Embolization Agents Company, Product Type & Application
  7. 3.7 Global Uterine Fibroid Embolization Agents Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Uterine Fibroid Embolization Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Uterine Fibroid Embolization Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Uterine Fibroid Embolization Agents Tier 1, Tier 2, and Tier 3
4 Uterine Fibroid Embolization Agents Regional Status and Outlook
  1. 4.1 Global Uterine Fibroid Embolization Agents Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Uterine Fibroid Embolization Agents Historic Market Size by Region
  3. 4.2.1 Global Uterine Fibroid Embolization Agents Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Uterine Fibroid Embolization Agents Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Uterine Fibroid Embolization Agents Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Region
  7. 4.3.1 Global Uterine Fibroid Embolization Agents Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Uterine Fibroid Embolization Agents Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Uterine Fibroid Embolization Agents Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Uterine Fibroid Embolization Agents by Application
  1. 5.1 Uterine Fibroid Embolization Agents Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Surgical Centers
  4. 5.1.3 Clinical Research Institutes
  5. 5.1.4 Others
  6. 5.2 Global Uterine Fibroid Embolization Agents Market Size by Application
  7. 5.2.1 Global Uterine Fibroid Embolization Agents Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Uterine Fibroid Embolization Agents Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Uterine Fibroid Embolization Agents Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Uterine Fibroid Embolization Agents Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Uterine Fibroid Embolization Agents Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Uterine Fibroid Embolization Agents Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Uterine Fibroid Embolization Agents Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Uterine Fibroid Embolization Agents Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 Boston Scientific Corporation
  8. 6.2.1 Boston Scientific Corporation Company Information
  9. 6.2.2 Boston Scientific Corporation Business Overview
  10. 6.2.3 Boston Scientific Corporation Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boston Scientific Corporation Uterine Fibroid Embolization Agents Product Portfolio
  12. 6.2.5 Boston Scientific Corporation Recent Developments
  13. 6.3 Nippon Kayaku
  14. 6.3.1 Nippon Kayaku Company Information
  15. 6.3.2 Nippon Kayaku Business Overview
  16. 6.3.3 Nippon Kayaku Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Nippon Kayaku Uterine Fibroid Embolization Agents Product Portfolio
  18. 6.3.5 Nippon Kayaku Recent Developments
  19. 6.4 Merit Medical Systems
  20. 6.4.1 Merit Medical Systems Company Information
  21. 6.4.2 Merit Medical Systems Business Overview
  22. 6.4.3 Merit Medical Systems Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merit Medical Systems Uterine Fibroid Embolization Agents Product Portfolio
  24. 6.4.5 Merit Medical Systems Recent Developments
  25. 6.5 Cook Medical
  26. 6.5.1 Cook Medical Company Information
  27. 6.5.2 Cook Medical Business Overview
  28. 6.5.3 Cook Medical Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cook Medical Uterine Fibroid Embolization Agents Product Portfolio
  30. 6.5.5 Cook Medical Recent Developments
  31. 6.6 Astellas Pharma
  32. 6.6.1 Astellas Pharma Company Information
  33. 6.6.2 Astellas Pharma Business Overview
  34. 6.6.3 Astellas Pharma Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Astellas Pharma Uterine Fibroid Embolization Agents Product Portfolio
  36. 6.6.5 Astellas Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Uterine Fibroid Embolization Agents Sales by Country
  2. 7.1.1 North America Uterine Fibroid Embolization Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Uterine Fibroid Embolization Agents Sales by Country (2021-2026)
  4. 7.1.3 North America Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032)
  5. 7.2 North America Uterine Fibroid Embolization Agents Market Size by Country
  6. 7.2.1 North America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Uterine Fibroid Embolization Agents Market Size by Country (2021-2026)
  8. 7.2.3 North America Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Uterine Fibroid Embolization Agents Sales by Country
  2. 8.1.1 Europe Uterine Fibroid Embolization Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Uterine Fibroid Embolization Agents Sales by Country (2021-2026)
  4. 8.1.3 Europe Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Uterine Fibroid Embolization Agents Market Size by Country
  6. 8.2.1 Europe Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Uterine Fibroid Embolization Agents Market Size by Country (2021-2026)
  8. 8.2.3 Europe Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Uterine Fibroid Embolization Agents Sales by Country
  2. 9.1.1 Asia-Pacific Uterine Fibroid Embolization Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Uterine Fibroid Embolization Agents Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Uterine Fibroid Embolization Agents Market Size by Country
  6. 9.2.1 Asia-Pacific Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Uterine Fibroid Embolization Agents Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Uterine Fibroid Embolization Agents Sales by Country
  2. 10.1.1 South America Uterine Fibroid Embolization Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Uterine Fibroid Embolization Agents Sales by Country (2021-2026)
  4. 10.1.3 South America Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032)
  5. 10.2 South America Uterine Fibroid Embolization Agents Market Size by Country
  6. 10.2.1 South America Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Uterine Fibroid Embolization Agents Market Size by Country (2021-2026)
  8. 10.2.3 South America Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country
  2. 11.1.1 Middle East and Africa Uterine Fibroid Embolization Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Uterine Fibroid Embolization Agents Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Uterine Fibroid Embolization Agents Market Size by Country
  6. 11.2.1 Middle East and Africa Uterine Fibroid Embolization Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Uterine Fibroid Embolization Agents Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Uterine Fibroid Embolization Agents Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Uterine Fibroid Embolization Agents Value Chain Analysis
  2. 12.1.1 Uterine Fibroid Embolization Agents Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Uterine Fibroid Embolization Agents Production Mode & Process
  7. 12.2 Uterine Fibroid Embolization Agents Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Uterine Fibroid Embolization Agents Distributors
  10. 12.2.3 Uterine Fibroid Embolization Agents Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst